Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PRKCA_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PRKCA_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PRKCA_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PRKCA_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/PRKCA_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRKCA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PRKCA_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRKCA_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PRKCA_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PRKCA_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKCA_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
GO:00452169 | Cervix | CC | cell-cell junction organization | 53/2311 | 200/18723 | 3.83e-08 | 2.53e-06 | 53 |
GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:00506787 | Cervix | CC | regulation of epithelial cell proliferation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:00106349 | Cervix | CC | positive regulation of epithelial cell migration | 47/2311 | 176/18723 | 1.73e-07 | 8.01e-06 | 47 |
GO:190370610 | Cervix | CC | regulation of hemopoiesis | 80/2311 | 367/18723 | 2.14e-07 | 9.55e-06 | 80 |
GO:00343298 | Cervix | CC | cell junction assembly | 88/2311 | 420/18723 | 3.42e-07 | 1.38e-05 | 88 |
GO:00064029 | Cervix | CC | mRNA catabolic process | 56/2311 | 232/18723 | 4.81e-07 | 1.83e-05 | 56 |
GO:00022379 | Cervix | CC | response to molecule of bacterial origin | 78/2311 | 363/18723 | 5.55e-07 | 2.06e-05 | 78 |
GO:00324969 | Cervix | CC | response to lipopolysaccharide | 74/2311 | 343/18723 | 9.15e-07 | 3.25e-05 | 74 |
GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517121 | Stomach | CAG with IM | Coronavirus disease - COVID-19 | 68/640 | 232/8465 | 9.36e-24 | 1.49e-21 | 1.04e-21 | 68 |
hsa0541521 | Stomach | CAG with IM | Diabetic cardiomyopathy | 56/640 | 203/8465 | 2.41e-18 | 1.10e-16 | 7.69e-17 | 56 |
hsa0502221 | Stomach | CAG with IM | Pathways of neurodegeneration - multiple diseases | 82/640 | 476/8465 | 4.27e-13 | 1.24e-11 | 8.67e-12 | 82 |
hsa0541721 | Stomach | CAG with IM | Lipid and atherosclerosis | 37/640 | 215/8465 | 1.61e-06 | 2.43e-05 | 1.71e-05 | 37 |
hsa0467021 | Stomach | CAG with IM | Leukocyte transendothelial migration | 22/640 | 114/8465 | 3.55e-05 | 4.03e-04 | 2.83e-04 | 22 |
hsa0472321 | Stomach | CAG with IM | Retrograde endocannabinoid signaling | 26/640 | 148/8465 | 3.97e-05 | 4.35e-04 | 3.05e-04 | 26 |
hsa051642 | Stomach | CAG with IM | Influenza A | 26/640 | 171/8465 | 4.49e-04 | 4.08e-03 | 2.87e-03 | 26 |
hsa0516321 | Stomach | CAG with IM | Human cytomegalovirus infection | 31/640 | 225/8465 | 7.66e-04 | 5.94e-03 | 4.17e-03 | 31 |
hsa0517021 | Stomach | CAG with IM | Human immunodeficiency virus 1 infection | 29/640 | 212/8465 | 1.26e-03 | 8.93e-03 | 6.27e-03 | 29 |
hsa0406621 | Stomach | CAG with IM | HIF-1 signaling pathway | 18/640 | 109/8465 | 1.26e-03 | 8.93e-03 | 6.27e-03 | 18 |
hsa05146 | Stomach | CAG with IM | Amoebiasis | 15/640 | 102/8465 | 9.37e-03 | 4.97e-02 | 3.48e-02 | 15 |
hsa0517131 | Stomach | CAG with IM | Coronavirus disease - COVID-19 | 68/640 | 232/8465 | 9.36e-24 | 1.49e-21 | 1.04e-21 | 68 |
hsa0541531 | Stomach | CAG with IM | Diabetic cardiomyopathy | 56/640 | 203/8465 | 2.41e-18 | 1.10e-16 | 7.69e-17 | 56 |
hsa0502231 | Stomach | CAG with IM | Pathways of neurodegeneration - multiple diseases | 82/640 | 476/8465 | 4.27e-13 | 1.24e-11 | 8.67e-12 | 82 |
hsa0541731 | Stomach | CAG with IM | Lipid and atherosclerosis | 37/640 | 215/8465 | 1.61e-06 | 2.43e-05 | 1.71e-05 | 37 |
hsa0467031 | Stomach | CAG with IM | Leukocyte transendothelial migration | 22/640 | 114/8465 | 3.55e-05 | 4.03e-04 | 2.83e-04 | 22 |
hsa0472331 | Stomach | CAG with IM | Retrograde endocannabinoid signaling | 26/640 | 148/8465 | 3.97e-05 | 4.35e-04 | 3.05e-04 | 26 |
hsa051643 | Stomach | CAG with IM | Influenza A | 26/640 | 171/8465 | 4.49e-04 | 4.08e-03 | 2.87e-03 | 26 |
hsa0516331 | Stomach | CAG with IM | Human cytomegalovirus infection | 31/640 | 225/8465 | 7.66e-04 | 5.94e-03 | 4.17e-03 | 31 |
hsa0517031 | Stomach | CAG with IM | Human immunodeficiency virus 1 infection | 29/640 | 212/8465 | 1.26e-03 | 8.93e-03 | 6.27e-03 | 29 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKCA | SNV | Missense_Mutation | novel | c.756N>T | p.Arg252Ser | p.R252S | P17252 | protein_coding | tolerated(0.14) | benign(0.1) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
PRKCA | SNV | Missense_Mutation | rs776243082 | c.430N>A | p.Val144Ile | p.V144I | P17252 | protein_coding | tolerated(0.19) | benign(0.059) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
PRKCA | SNV | Missense_Mutation | novel | c.1621N>A | p.Glu541Lys | p.E541K | P17252 | protein_coding | deleterious(0.01) | benign(0.397) | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PRKCA | insertion | Frame_Shift_Ins | novel | c.788_789insGGCA | p.Ser264AlafsTer17 | p.S264Afs*17 | P17252 | protein_coding | | | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
PRKCA | insertion | Frame_Shift_Ins | novel | c.789_790insGATCTCAGCTCACTGCAGCCTCCGCC | p.Ser264AspfsTer12 | p.S264Dfs*12 | P17252 | protein_coding | | | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
PRKCA | insertion | Nonsense_Mutation | novel | c.353_354insAATGATCCATTTAGGGTTGTTCTGTTCACTTCACAAACACACCGATT | p.Cys118Ter | p.C118* | P17252 | protein_coding | | | TCGA-BH-A1FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRKCA | SNV | Missense_Mutation | novel | c.1663N>A | p.Val555Ile | p.V555I | P17252 | protein_coding | tolerated(0.07) | benign(0.213) | TCGA-HM-A3JJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
PRKCA | SNV | Missense_Mutation | rs140466753 | c.1895G>A | p.Arg632Gln | p.R632Q | P17252 | protein_coding | tolerated(0.07) | benign(0.029) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRKCA | SNV | Missense_Mutation | novel | c.1627G>A | p.Glu543Lys | p.E543K | P17252 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCA | SNV | Missense_Mutation | | c.916N>A | p.Glu306Lys | p.E306K | P17252 | protein_coding | tolerated(0.15) | benign(0.014) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5578 | PRKCA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME | inhibitor | 178102320 | ENZASTAURIN | |
5578 | PRKCA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME | | BRYOSTATIN | BRYOSTATIN | 22579485 |
5578 | PRKCA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME | inhibitor | SOPHORETIN | QUERCETIN | |
5578 | PRKCA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME | | Sodium phenylbutyrate | | |
5578 | PRKCA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME | inhibitor | 178101880 | | |
5578 | PRKCA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME | | hydrochlorothiazide | HYDROCHLOROTHIAZIDE | |
5578 | PRKCA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME | inhibitor | MIDOSTAURIN | MIDOSTAURIN | |
5578 | PRKCA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME | | BRYOSTATIN-1 | | |
5578 | PRKCA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME | inhibitor | 178102596 | | |
5578 | PRKCA | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME | | ENOXOLONE | ENOXOLONE | 24461294 |